Drug Identification Guide - Drug Identifier News

Drug Identifier News

Apps for what ails you Monday, March 8, 2010 @ 5:56AMNeed an extra push to quit smoking? Next time grab your iPhone instead of a cigarette.
Slowly Maturing, Semantic Web Technologies Reach Pilot Project Stage in Pharma Wednesday, March 3, 2010 @ 3:30PMSemantic technology appears to be slowly finding its way into pharma's informatics toolbox, as proponents of the technology reported at a recent conference that they are moving beyond prototypes and into pilot projects that put semantic technologies to work.
New Clinical Pharmacology Mobile released to support routine medication information needs Monday, March 1, 2010 @ 5:34AMGold Standard/Elsevier (http://www.goldstandard.com), a leading provider of drug decision support announced today the availability of Clinical Pharmacology Mobile, a mobile device-optimized web site offering users access to the features and functions of Clinical Pharmacology, an award-winning electronic drug information and medication management reference.
Gold Standard/Elsevier Launches Clinical Pharmacology Mobile Monday, March 1, 2010 @ 4:30AM-
Press Release Friday, February 26, 2010 @ 6:25AMNUREMBERG, Germany, February 26, 2010 /PRNewswire/ -- Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE. This phase III trial is evaluating the safety and efficacy of edoxaban in the treatment and prevention of recurrent thromboembolic events in patients with deep-vein thrombosis (DVT) and/or ...
HOKUSAI VTE - Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe Friday, February 26, 2010 @ 4:17AMNuremberg, Germany, February 26, 2010 (ots/PRNewswire) - Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale ...
HOKUSAI VTE - Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe Friday, February 26, 2010 @ 4:16AMNuremberg, Germany, February 26, 2010 (ots/PRNewswire) - Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE. This phase III trial ...
Epocrates Brings Gold-Standard Product to Palm webOS Smartphones Thursday, February 25, 2010 @ 7:05AMSAN MATEO, Calif.----Epocrates, Inc., developer of the most popular medical reference tools, today announced that healthcare professionals can now use a beta version of its software on mobile devices running the Palm® webOS™ platform – including the Palm Pre™ and Palm Pixi™ smartphones.
Sun Knowledge, Ltd. Announces Positive Outcome at Benefit Management Institute's Drug Benefit Conference Wednesday, February 24, 2010 @ 8:35AMNEW YORK----Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing services is pleased to announce a successful showing at the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az.
Kids team to mourn their mentor Thursday, February 18, 2010 @ 7:00AMFOR the children he had coached, there are grief counsellors. For Ian Gray's colleagues and friends in the soccer community, there is just disbelief.
Health and Security Technology Stock Alert for PositiveID Corp. Issued by Beacon Equity Wednesday, February 17, 2010 @ 5:50AMDALLAS -- BeaconEquity.com announces an investment report featuring PositiveID Corp. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Health and Security Technology Stock Alert for PositiveID Corp. Issued by Beacon Equity Wednesday, February 17, 2010 @ 5:50AMDALLAS -- BeaconEquity.com announces an investment report featuring PositiveID Corp. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Sun Knowledge, Ltd. To Demonstrate Its Unique, Proprietary Offerings To Pharmacy Benefit Managers at Conference Tuesday, February 16, 2010 @ 8:35AMNEW YORK----Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing services, will attend the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az., from February 17-19.
Pharmacists: An Under-Used Part of Health Care Monday, February 15, 2010 @ 5:40AMTheir years of training make them 'walking encyclopedias' on drug effectiveness, side effects and interactions. There's an old Jerry Seinfeld joke many pharmacists know all too well. It's the one in which he describes their "whole job" as taking pills from a big bottle and putting them in a little bottle.
Pharmacists: An Under-Used Part of Health Care Monday, February 15, 2010 @ 5:40AMTheir years of training make them 'walking encyclopedias' on drug effectiveness, side effects and interactions. There's an old Jerry Seinfeld joke many pharmacists know all too well. It's the one in which he describes their "whole job" as taking pills from a big bottle and putting them in a little bottle.
Sun Knowledge, Ltd. to Attend Pharmacy Benefit Management Institute's (PBMI) Drug Benefit Conference Thursday, February 11, 2010 @ 8:35AMNEW YORK----Sun Knowledge, Ltd., a leading Healthcare Insurance provider of Knowledge Process Outsourcing services, will attend the Pharmacy Benefit Management Institute’s Annual Drug Benefit Conference in Phoenix, Az., from February 17-19.
Without a trace Wednesday, February 10, 2010 @ 12:34PMOur food supply chain is large, complex, and diverse, and traceability in food and pharmaceutical products is a life-critical issue.
Awareness of Heart Disease in Women Remains Low Wednesday, February 10, 2010 @ 6:30AMCardiovascular disease is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.
Google Has More Than Android On Its Platform Thursday, February 4, 2010 @ 6:27PM(PhysOrg.com) -- In the last several weeks, we've read a bit about how Google is getting restless just being the world`s largest search engine and a proud cloud computing parent. In fact, Googleland is growing by quantum leaps and bounds.
Will Sequenom's New Genotyping Test for Fetal RhD Encounter Firm's Market Expectations? Thursday, February 4, 2010 @ 9:00AMSequenom today said it has launched its SensiGene fetal RHD genotyping test for use in first-trimester pregnancies, which it says is better than real-time PCR assays that test for similar abnormalities.
International Drug & Explosives Detection Firm IDenta Corp Issues Update on IDenta Alert Explosive Identifier, Marketing Wednesday, February 3, 2010 @ 10:34AMJERUSALEM--(Marketwire - February 3, 2010) - IDenta Corp. ( PINKSHEETS : IDTA ) CEO Yaacov Shoham today announced the following marketing updates concerning IDenta Alert Explosive Identifiers: 1. USA Army - the 100,000 kits, the final order should be any day. (waiting for the final signature). We do expect that this will open the doors for many other army units. 2. Navy - we have sent them - by ...
Nuvilex, Inc. Announces that Legacy Biotechnologies' Reme-Flu with Syn-X9 Formulation Receives FDA National Drug Code ... Tuesday, February 2, 2010 @ 3:15PMCHERRY HILL, N.J.----Nuvilex, Inc. , announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has received its National Drug Code numbers , from the Food and Drug Administration for its homeopathic flu remedy.
New Web site makes crime statistics available to Sheman citizens Monday, February 1, 2010 @ 9:56PMSherman Police Department has opened up its crime statistics to the public by way of a Web site the department obtained through a grant. Sherman police Capt. Otis Henry said the Web site, www.crimereports.com, is updated once every 24-hour period.
FDA plans agressive overhaul of 510(k); unique device identifier coming in 2013 Wednesday, January 27, 2010 @ 3:27PMMeet the new boss, who is definitely not the same as the old boss. The Center for Devices and Radiological Health and new director Jeffrey Shuren are looking to shake things up at the Food & Drug Administration's medical device oversight arm, according to a new set of strategic priorities for 2010 and the following years. The changes include an overhaul of the 510(k) and PMA approval processes ...
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial ... Tuesday, January 26, 2010 @ 3:44PMContext Antiarrhythmic drugs are commonly used for prevention of recurrent atrial fibrillation (AF) despite inconsistent efficacy and frequent adverse effects. Catheter ablation has been proposed as an alternative treatment for paroxysmal AF. Objective To determine the efficacy of catheter ablation compared with antiarrhythmic drug therapy (ADT) in treating symptomatic paroxysmal AF. Design ...
NCPDP Announces 2010 Annual Technology & Business Conference Tuesday, January 26, 2010 @ 7:37AMSCOTTSDALE, Ariz.----The National Council for Prescription Drug Programs announced today its 2010 Annual Technology & Business Conference will be held at the Arizona Biltmore Resort, May 2-6, 2010.
Exclusive: Perry voter turnout project signs up felons Sunday, January 24, 2010 @ 2:39AMGov. Rick Perry 's campaign has unknowingly paid convicted felons as part-time workers under its incentive program to turn out voters for the Republican primary.
Exclusive: Perry voter turnout project signs up felons Saturday, January 23, 2010 @ 11:46PMTexas Gov. Rick Perry 's campaign has unknowingly paid convicted felons as part-time workers under its incentive program to turn out voters for the Republican primary.
Motorola's Mobile Loyalty Solution Wednesday, January 20, 2010 @ 9:32AMRecognizing consumers' need to use mobile phones while shopping, Motorola has launched Mobile Loyalty Solution, which serves as an extension of existing loyalty card programs or as the basis for new digital efforts.
Lantheus Medical Imaging, Inc. Launches ABLAVAR (Gadofosveset Trisodium), a New Diagnostic Magnetic Resonance ... Wednesday, January 20, 2010 @ 5:30AMNORTH BILLERICA, Mass.----Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the launch of ABLAVAR™ , a unique, injectable MRA imaging agent used to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease .
"THE EVENT" on March 13 is Pacquiao's day of judgment! Tuesday, January 19, 2010 @ 5:49PMI must confess Pacquiao's reputation in the eyes of the American public has now reached the crossroads of trials. Of course, he has no tribulations at this time.
Motorola's Mobile Loyalty Solution Targets Shoppers Tuesday, January 19, 2010 @ 1:22PMRecognizing consumers’ need to use mobile phones while shopping, Motorola launched a Mobile Loyalty Solution, which serves as an extension of existing loyalty card programs or as the basis for new digital ones.
VA Wins National Award for Safe Medication Practices Tuesday, January 19, 2010 @ 12:30PMWASHINGTON, Jan. 19 /PRNewswire-USNewswire/ -- The Department of Veterans Affairs (VA) has won top national honors from the independent Institute for Safe Medication Practices for its excellence in preventing medication errors.
Motorola Empowers Retailers To Mobilize Customer Loyalty Programs Tuesday, January 12, 2010 @ 11:07PMThe Enterprise Mobility Solutions division of Motorola, Inc. recently announced its Mobile Loyalty Solution - the retail industry's most comprehensive managed service that enables retailers to foster a more personal relationship with their customers and digitize store-branded membership cards on customers' mobile phones.
ABRF's iPRG Extends Submission Deadline for Study Tuesday, January 12, 2010 @ 11:30AMThis story originally ran on Jan. 12. The Proteome Informatics Research Group of the Association of Biomolecular Resource Facilities said this week it is pushing back the deadline to submit results for this year's study to Jan. 18.
Motorola Empowers Retailers to Mobilize Customer Loyalty Programs Monday, January 11, 2010 @ 7:00AMNRF 2010 -- The Enterprise Mobility Solutions division of Motorola, Inc. today announced its Mobile Loyalty Solution â the retail industry's most comprehensive managed service that enables retailers to foster a more personal relationship with their customers and digitize store-branded membership cards on customers' mobile phones.
Oraya Therapeutics Initiates First Ever Sham-Controlled Study Of Radiation Therapy For Wet AMD Thursday, January 7, 2010 @ 10:29AMOraya Therapeutics, Inc., announced that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of ...
Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD Tuesday, January 5, 2010 @ 9:45AMNEWARK, Calif.----Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration .
Tips on Generics Friday, December 18, 2009 @ 6:35PMKeep records of how a generic drug affects you, and enlist your doctor’s help if you have concerns..
EANS-News: Epigenomics AG: PRESEPT Study Subject Enrollment Successfully Completed Thursday, December 17, 2009 @ 4:23AM7,852 subjects prospectively enrolled including more than 50 cancer cases Blood samples selected for testing by independent biostatistics group Septin9 testing in three independent laboratories on track; majority of samples tested Completion of PRESEPT Study and reporting of top-line results expected for early 2010
FYI from Human Genome Sciences: GSK Initiates Second Pivotal Phase 3 Trial for Investigational Cardiovascular ... Wednesday, December 9, 2009 @ 8:14AMROCKVILLE, Md.----Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome .
Psychological trauma leaves a trail of damage in a child's brain, reveal scientists Wednesday, December 9, 2009 @ 3:00AMPsychological trauma leaves a trail of damage in a child's brain, say scientists at the Stanford University School of Medicine and Lucile Packard Children's Hospital. Their new study gives the first direct evidence that children with symptoms of post-traumatic stress suffer poor function of the hippocampus, a brain structure that stores and retrieves memories. The research helps explain why ...
Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA Thursday, December 3, 2009 @ 8:33AMEndo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.
Police & fire reports Wednesday, December 2, 2009 @ 4:30PMCheck out police and fire reports for Downers Grove, Westmont and Woodridge.
NCPDP Announces Call for Nominations for 2010 Industry Leadership Awards Wednesday, December 2, 2009 @ 12:12PMSCOTTSDALE, Ariz.----The National Council for Prescription Drug Programs , a not-for-profit pharmacy standards development organization, announced today the call for nominations for its 2010 leadership awards.
Women with gestational glucose intolerance at risk of metabolic syndrome Tuesday, December 1, 2009 @ 3:49AMWomen who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
454 Life Sciences to launch sequencing platform GS Junior System in 2010 Saturday, November 28, 2009 @ 4:51AM454 Life Sciences, a Roche Company, announced at the Association of Molecular Pathology Annual Meeting in Kissimmee, Florida a series of revolutionary developments which significantly expand the company’s high-throughput sequencing portfolio.
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial [Original Contribution] Tuesday, November 24, 2009 @ 3:39PMContext Intravenous access and drug administration are included in advanced cardiac life support (ACLS) guidelines despite a lack of evidence for improved outcomes. Epinephrine was an independent predictor of poor outcome in a large epidemiological study, possibly due to toxicity of the drug or cardiopulmonary resuscitation (CPR) interruptions secondary to establishing an intravenous line and ...
AMA meeting: Better data protection needed from Blues Sunday, November 22, 2009 @ 8:51PMNew AMA policy says the national insurer needs to expand its offer of credit protection for doctors whose information was on a stolen laptop.
454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System ... Thursday, November 19, 2009 @ 10:00AMBRANFORD, Conn.----454 Life Sciences, a Roche Company , announced today at the Association of Molecular Pathology Annual Meeting in Kissimmee, Florida a series of revolutionary developments which significantly expand the company’s high-throughput sequencing portfolio.